Immunotherapy for Chronic Hepatitis B Virus Infection

키워드

참고문헌 (101)

1. Stanaway JD, "The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013", Lancet, 388, pp.1081~1088 (2016)[DOI]
2. Foster GR, "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection", N Engl J Med, 373, pp.2608~2617 (2015)[DOI]
3. Gish RG, "Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities", Antiviral Res, 121, pp.47~58 (2015)[DOI]
4. Block TM, "Chronic hepatitis B: what should be the goal for new therapies?", Antiviral Res, 98, pp.27~34 (2013)[DOI]
5. Zoulim F, "Current treatments for chronic hepatitis B virus infections", Curr Opin Virol, 18, pp.109~116 (2016)[DOI]
6. Gill US, "Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?", J Infect Dis, 211, pp.374~382 (2015)[DOI]
7. Ilan Y, "Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation", Hepatology, 18, pp.246~252 (1993)
8. Lau GK, "Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer", Hepatology, 25, pp.1497~1501 (1997)[DOI]
9. Maini MK, "The role of innate immunity in the immunopathology and treatment of HBV infection", J Hepatol, 64(1 Suppl), pp.S60~S70 (2016)[DOI]
10. Sato S, "The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus", Immunity, 42, pp.123~132 (2015)[DOI]
11. Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", Science, 343, pp.1221~1228 (2014)[DOI]
12. Belloni L, "IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome", J Clin Invest, 122, pp.529~537 (2012)[DOI]
13. McClary H, "Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines", J Virol, 74, pp.2255~2264 (2000)[DOI]
14. Watashi K, "Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)", J Biol Chem, 288, pp.31715~31727 (2013)[DOI]
15. Liaw YF, "Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection", Gastroenterology, 126, pp.1024~1029 (2004)[DOI]
16. Sagnelli E, "HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course", Hepatology, 36, pp.1285~1291 (2002)[DOI]
17. Bertoletti A, "Hepatitis B: future curative strategies", Curr Opin Infect Dis, 27, pp.528~534 (2014)[DOI]
18. Maini MK, "NK cells: a double-edged sword in chronic hepatitis B virus infection", Front Immunol, 4, pp.57~ (2013)
19. Thimme R, "Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?", J Hepatol, 58, pp.205~209 (2013)
20. Fisicaro P, "Early kinetics of innate and adaptive immune responses during hepatitis B virus infection", Gut, 58, pp.974~982 (2009)[DOI]
21. Webster GJ, "Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms", Hepatology, 32, pp.1117~1124 (2000)[DOI]
22. Peppa D, "Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion", J Exp Med, 210, pp.99~114 (2013)[DOI]
23. Oliviero B, "Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections", J Hepatol, 55, pp.53~60 (2011)[DOI]
24. Yeo W, "Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab", J Clin Oncol, 27, pp.605~611 (2009)[DOI]
25. Zhang TY, "Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen", Gut, 65, pp.658~671 (2016)[DOI]
26. Thimme R, "CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection", J Virol, 77, pp.68~76 (2003)[DOI]
27. Ferrari C, "Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection", J Immunol, 145, pp.3442~3449 (1990)
28. Penna A, "Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen", J Exp Med, 174, pp.1565~1570 (1991)[DOI]
29. Maini MK, "Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection", Gastroenterology, 117, pp.1386~1396 (1999)[DOI]
30. Bertoletti A, "Adaptive immunity in HBV infection", J Hepatol, 64(1 Suppl), pp.S71~S83 (2016)[DOI]
31. Shouval D, "Immunosuppression and HBV reactivation", Semin Liver Dis, 33, pp.167~177 (2013)[DOI]
32. Wieland SF, "Intrahepatic induction of alpha", beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice, 2000, pp.74, 4165~4173
33. Puro R, "Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA", J Virol, 81, pp.7351~7362 (2007)[DOI]
34. Bertoletti A, "Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?", PLoS Pathog, 9, pp.e1003784~ (2013)[DOI]
35. Zoulim F, "Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B", Gastroenterology, 144, pp.1342~1344 (2013)[DOI]
36. Guo F, "STING agonists induce an innate antiviral immune response against hepatitis B virus", Antimicrob Agents Chemother, 59, pp.1273~1281 (2015)[DOI]
37. Lanford RE, "GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees", Gastroenterology, 144, pp.1508~1517 (2013)[DOI]
38. Menne S, "Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B", J Hepatol, 62, pp.1237~1245 (2015)
39. Gane EJ, "The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection", J Hepatol, 63, pp.320~328 (2015)[DOI]
40. Jo J, "Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver", PLoS Pathog, 10, pp.e1004210~ (2014)[DOI]
41. Tang XZ, "IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells", J Immunol, 190, pp.3142~3152 (2013)[DOI]
42. Schurich A, "The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBVspecific CD8 T cells", PLoS Pathog, 9, pp.e1003208~ (2013)[DOI]
43. Ji C, "Targeted delivery of interferon-alpha to hepatitis B virus-infected cells using T-cell receptorlike antibodies", Hepatology, 56, pp.2027~2038 (2012)[DOI]
44. Gehring AJ, "Mobilizing monocytes to cross-present circulating viral antigen in chronic infection", J Clin Invest, 123, pp.3766~3776 (2013)[DOI]
45. Sastry KS, "Targeting hepatitis B virusinfected cells with a T-cell receptor-like antibody", J Virol, 85, pp.1935~1942 (2011)[DOI]
46. Boni C, "Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection", J Virol, 81, pp.4215~4225 (2007)[DOI]
47. Fisicaro P, "Antiviral intrahepatic Tcell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B", Gastroenterology, 138, pp.682~693 (2010)[DOI]
48. Daud AI, "Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma", J Clin Invest, 126, pp.3447~3452 (2016)[DOI]
49. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)[DOI]
50. Fuller MJ, "Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)", Proc Natl Acad Sci U S A, 110, pp.15001~15006 (2013)[DOI]
51. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
52. Michel ML, "Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges", J Hepatol, 54, pp.1286~1296 (2011)[DOI]
53. Liu J, "New therapeutic vaccination strategies for the treatment of chronic hepatitis B", Virol Sin, 29, pp.10~16 (2014)[DOI]
54. Kosinska AD, "Combination of DNA prime: adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model", PLoS Pathog, 9, pp.e1003391~ (2013)[DOI]
55. Michel ML, "Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future", Vaccine, 19, pp.2395~2399 (2001)[DOI]
56. Mancini-Bourgine M, "Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers", Hepatology, 40, pp.874~882 (2004)
57. Vandepapeliere P, "Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg", AS02 candidate vaccine and lamivudine, 2007, pp.25, 8585~8597
58. Xu DZ, "Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings", J Hepatol, 59, pp.450~456 (2013)[DOI]
59. Godon O, "Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues", Mol Ther, 22, pp.675~684 (2014)[DOI]
60. Lok AS, "Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B", J Hepatol, 65, pp.509~516 (2016)[DOI]
61. Liu J, "Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PDL1 blockade in chronic hepadnaviral infection", PLoS Pathog, 10, pp.e1003856~ (2014)[DOI]
62. Wu W, "Blockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis B", Eur J Immunol, 42, pp.1180~1191 (2012)[DOI]
63. Kurktschiev PD, "Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction", J Exp Med, 211, pp.2047~2059 (2014)[DOI]
64. Bengsch B, "Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation", J Hepatol, 61, pp.1212~1219 (2014)[DOI]
65. Schurich A, "Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host", Cell Rep, 16, pp.1243~1252 (2016)[DOI]
66. Fisicaro P, "Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBVspecific CD8 T cells in chronic hepatitis B", Nat Med, 23, pp.327~336 (2017)[DOI]
67. Koh S, "Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?", Med Microbiol Immunol, 204, pp.87~94 (2015)[DOI]
68. Loggi E, "Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft", J Hepatol, 50, pp.625~630 (2009)[DOI]
69. Bohne F, "T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes", Gastroenterology, 134, pp.239~247 (2008)[DOI]
70. Gehring AJ, "Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines", J Hepatol, 55, pp.103~110 (2011)[DOI]
71. Krebs K, "T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice", Gastroenterology, 145, pp.456~465 (2013)[DOI]
72. Qasim W, "Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient", J Hepatol, 62, pp.486~491 (2015)[DOI]
73. Kah J, "Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection", J Clin Invest, 127, pp.3177~3188 (2017)[DOI]
74. June CH, "Engineering lymphocyte subsets: tools, trials and tribulations", Nat Rev Immunol, 9, pp.704~716 (2009)[DOI]
75. Kaiser AD, "Towards a commercial process for the manufacture of genetically modified T cells for therapy", Cancer Gene Ther, 22, pp.72~78 (2015)[DOI]
76. Oates J, "ImmTACs for targeted cancer therapy: why, what, how, and which", Mol Immunol, 67(2), pp.67~74 (2015)[DOI]
77. Yang H, "Elimination of latently HIVinfected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptors", Mol Ther, 24, pp.1913~1925 (2016)[DOI]
78. Sitia G, "MMPs are required for recruitment of antigennonspecific mononuclear cells into the liver by CTLs", J Clin Invest, 113, pp.1158~1167 (2004)[DOI]
79. Ando K, "Mechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis", J Exp Med, 178, pp.1541~1554 (1993)[DOI]
80. Maini MK, "The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection", J Exp Med, 191, pp.1269~1280 (2000)[DOI]
81. Kennedy PT, "Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B", Gastroenterology, 143, pp.637~645 (2012)[DOI]
82. Mason WS, "HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant", Gastroenterology, 151, pp.986~998 (2016)[DOI]
83. Pallett LJ, "IL-2(high) tissue-resident T cells in the human liver: Sentinels for hepatotropic infection", J Exp Med, 214, pp.1567~1580 (2017)[DOI]
84. Pallett LJ, "Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells", Nat Med, 21, pp.591~600 (2015)[DOI]
85. Sandalova E, "Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells", Gastroenterology, 143, pp.78~87 (2012)[DOI]
86. Das A, "Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection", J Exp Med, 205, pp.2111~2124 (2008)[DOI]
87. Xu D, "Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B", J Immunol, 177, pp.739~747 (2006)[DOI]
88. Sitia G, "Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis", PLoS Pathog, 7, pp.e1002061~ (2011)[DOI]
89. Tan-Garcia A, "Intrahepatic CD206(+) macrophages contribute to inflammation in advanced viralrelated liver disease", J Hepatol, 67, pp.490~500 (2017)[DOI]
90. Koh S, "A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus", Mol Ther Nucleic Acids, 2, pp.e114~ (2013)[DOI]
91. Petersen J, "Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein", Nat Biotechnol, 26, pp.335~341 (2008)[DOI]
92. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)[DOI]
93. Zoulim F, "Reasons to consider earlier treatment of chronic HBV infections", Gut, 61, pp.333~336 (2012)[DOI]
94. Stabenow D, "Bioluminescence imaging allows measuring CD8 T cell function in the liver", Hepatology, 51, pp.1430~1437 (2010)[DOI]
95. Webster GJ, "Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy", J Virol, 78, pp.5707~5719 (2004)[DOI]
96. Kollmann TR, "Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly", Immunity, 37, pp.771~783 (2012)[DOI]
97. Bertoletti A, "The immune tolerant phase of chronic HBV infection: new perspectives on an old concept", Cell Mol Immunol, 12, pp.258~263 (2015)[DOI]
98. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)[DOI]
99. Beyer M, "Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection", Nat Immunol, 17, pp.593~603 (2016)[DOI]
100. Gotto J, "The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine", J Viral Hepat, 13, pp.415~425 (2006)[DOI]
101. Carey I, "Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy", J Virol, 85, pp.2416~2428 (2011)[DOI]

관련 논문AI추천